Group items tagged

This Funding Opportunity Announcement (FOA) intends to support a Brain Cell Data Center (BCDC) that will work with other BICCN Centers and interested researchers to establish a web-accessible information system to capture, store, analyze, curate, and display all data and metadata on brain cell types, and their connectivity. The BCDC is expected to: (1) lead the effort to establish spatial and semantic standards for managing heterogeneous brain cell census data types and information; (2) lead the effort to collect and register multimodal brain cell census data to common brain coordinate systems; (3) generate searchable 2D and 3D digital brain atlases for cell census data; and (4) generate a unified and comprehensive brain cell knowledge base that integrates all existing brain cell census data and information across diverse repositories.  A central goal of this and the three companion FOAs is to build a brain cell census resource that can be widely used throughout the research community.

This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.

This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimer's disease. 

The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients.Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications (via limited competition) for SPARC Comprehensive Functional Mapping of Neuroanatomy and Neurobiology of Organs. These projects will comprehensively provide data for developing detailed, predictive functional and anatomical neural circuit maps for neural control of major functions of organs and their functionally-associated structures. 

This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas.The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing variations on magnetic or electrical stimulation, and that represent more than an incremental advance over existing electromagnetic approaches. The second distinct area that this FOA seeks to encourage is the optimization of existing electrical and magnetic stimulation methods.

The focus of this Funding Opportunity Announcement (FOA) is to better understand how existing non-invasive neuromodulation devices affect brain circuity. This information should shed light on dose/response relationships that could be used for neuroscience applications and clinical interventions.

The purpose of this Funding Opportunity Announcement is to encourage research on the basic biology of the intervertebral disc and on the molecular mechanisms underlying intervertebral disc degeneration. Back/spinal pain, which is a major public health concern in the United States, is strongly associated with intervertebral disc degeneration. Acute low back pain that is serious enough to disrupt daily routines affects about 70 percent of adults sometime during their lives. In the vast majority of patients, low back pain resolves within a few weeks with conservative medical management. 

This funding opportunity announcement (FOA) supports high impact efforts to make resources available to neuroscience researchers.  Projects should engage in one or more of the following activities: facilitating access to cutting edge reagents or techniques, dissemination of resources to new user groups, or innovative approaches to increase the scale/efficiency of resource production and delivery.  Applications focused primarily on technology or software development are not responsive to this FOA, as the focus is on dissemination or provision of resources.  Use of existing technologies to develop new reagents or genetic lines of significant value to the research community may be appropriate. Projects should address compelling needs of broad communities of neuroscience researchers or should offer unique services that otherwise would be unavailable.

The CDC Epilepsy Program is announcing a new, FY16 non-research FOAs designed to improve health and quality of life for people with epilepsy.

The purpose of this Funding Opportunity Announcement (FOA) is to advance research on male-females differences in drug and alcohol abuse and addiction and on factors specific to women.  Both human and animal model studies are sought. 

This Funding Opportunity Announcement (FOA) encourages applications from investigators that propose to study the developing brain or brain areas that play significant roles in mediating emotional and motivated behavior and in substance use and dependence.  All stages of brain development are of interest, but a new emphasis of the current reissue of this initiative is to support basic neuroscience research on fundamental mechanisms of brain development during prepuberty and the adolescent period in relation to the problems of substance abuse and co-morbidity with psychiatric disorders.  Topics of interest pertaining to brain development of this initiative include, but are not limited to, the euphoric properties of abused substances, actions of psychotherapeutic agents, and their consequences on memory, cognitive and emotional processes.  A major goal of this initiative is to understand how exposure to substances of abuse and environmental insults affects the cellular and molecular mechanisms underlying nervous system development and neural circuit functions implicated in substance use and addiction. 

This NIH Funding Opportunity Announcement (FOA) is part of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) Common Fund program. This FOA solicits applications for support of research to gather critical data and answer critical questions on functional peripheral neuroanatomy of organs and reveal the organ function controlled by neural circuits.   Organs of interest include those where the peripheral neuroanatomy and functional neurobiology of the organ have been understudied, and which are not the subject of existing SPARC funding under RFA-RM-15-018 (see below).  

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research on the role of the nervous system in metabolism, homeostasis, remodeling and/or regeneration of the postnatal dental and craniofacial skeletal system (DCS) in health and disease. The objectives are to enhance basic science knowledge about interactions between the peripheral and central nervous systems (PNS/CNS) and the DCS, and facilitate development of strategies to optimize normal function, reduce the impact of disease, and develop capacity to repair and regenerate injured teeth and craniofacial bones. 

Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health (NIMH) seeks applications to develop, sustain, enhance, and enrich a centralized national biorepository for genetic studies of psychiatric disorders for facilitation and acceleration of the scientific understanding of the genetic risk architecture underlying mental disorders. This effort is expected to involve a functionally integrated, multi-disciplinary team that will provide for open sharing of biosamples and data resources through a single, centralized, national resource to advance basic and translational research in the genetics of mental disorders.

This Funding Opportunity Announcement (FOA) is dedicated to the discovery of therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, and cell therapies) for disorders that fall under the NINDS mission.  It supports the optimization of therapeutic lead(s) showing convincing proof-of-concept.   At the end of the funding period, projects that successfully advance through support from this program will have identified a optimized candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE Bio Development track for further development to enable filing for an Investigational New Drug (IND).   

Genetic and genomic studies have identified genes and gene variants that may impact the fundamental biological mechanisms underpinning substance use disorders (SUDs).  Discovery of these genes/variants, while extremely valuable, is only the first step in understanding the molecular processes that influence SUDs. This Funding Opportunity Announcement (FOA) encourages basic functional genetic and genomic research in two areas:  1. functional validation to determine which candidate genes/variants/epigenetic/non-coding RNA features have an authentic role in SUDs, and 2. detailed elucidation of the molecular pathways and processes modulated by candidate genes/variants, particularly for those genes with an unanticipated role in SUDs.   

This funding opportunity announcement (FOA) is issued by the National Institute of Neurological Disorders and Stroke to enable submission of program project grant applications that propose to conduct innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants.